 |
 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Featured MNV Articles:
| The Implied Analyst 12-Month Target For XPHBy Dividend Channel Staff, Monday, December 4, 7:07 AM ET
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Pharmaceuticals ETF (NYSE:XPH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $60.95 per unit. With XPH trading at a recent price near $37.59 per unit, that means that analysts see 62.13% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of XPH's underlying holdings with notable upside to their analyst target prices are Ventyx Biosciences Inc (NASDAQ:VTYX), Arvinas Inc (NASDAQ:ARVN), and Ligand Pharmaceuticals Inc (NASDAQ:LGND). Although VTYX has traded at a recent price of $2.20/share, the average analyst target is 884.82% higher at $21.67/share. Similarly, ARVN has 128.55% upside from the recent share price of $23.60 if the average analyst target price of $53.94/share is reached, and analysts on average are expecting LGND to reach a target price of $111.50/share, which is 89.63% above the recent price of $58.80. Below is a twelve month price history chart comparing the stock performance of VTYX, ARVN, and LGND:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
This Article's Word Cloud:
ARVN
Analyst
Arvinas
Below
Biosciences
ETFs
FREEGet
LGND
Ligand
Pharmaceuticals
SPDR
Target
Upside
VTYX
Ventyx
With
Zacks
about
above
analyst
analysts
average
background
based
border
bottom
color
data
font
from
have
hctblstyle
holdings
implied
latest
mdash
month
padding
price
prices
recent
report
research
share
target
targets
that
trading
underlying
upside
|
Play Video:
The Importance of ETFs
Free Email Alerts By Stock:
Start slideshow: